Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Herz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
4SCan/vADME: intelligent library screening as a shortcut from hits to lead compoundsThomas Herz, Kristina Wolf, Juergen Kraus, et al.
Journal of Molecular Modeling|December 15, 2004
ProPose: a docking engine based on a fully configurable protein-ligand interaction modelMarkus H J Seifert, Frank Schmitt, Thomas Herz, et al.
Clinical Orthopaedics and Related Research|April 3, 2003
Accuracy of spinal navigation for magerl screwsThomas Herz, Alexander Franz, Salvatore M Giacomuzzi, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2009
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hoppingStefan Tasler, Oliver Müller, Tanja Wieber, et al.
Leukemia & Lymphoma|August 31, 2018
Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE studyJan Walewski, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, et al.
Antiviral Research|October 24, 2013
Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesisManfred Marschall, Ina Niemann, Karin Kosulin, et al.
Bioorganic & Medicinal Chemistry|August 21, 2009
Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimizationStefan Tasler, Oliver Müller, Tanja Wieber, et al.
Journal for Immunotherapy of Cancer|May 8, 2019
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapySonja Althammer, Tze Heng Tan, Andreas Spitzmüller, et al.
Journal of Hepatology|March 9, 2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
4SCan/vADME: intelligent library screening as a shortcut from hits to lead compoundsThomas Herz, Kristina Wolf, Juergen Kraus, et al.
Journal of Molecular Modeling|December 15, 2004
ProPose: a docking engine based on a fully configurable protein-ligand interaction modelMarkus H J Seifert, Frank Schmitt, Thomas Herz, et al.
Clinical Orthopaedics and Related Research|April 3, 2003
Accuracy of spinal navigation for magerl screwsThomas Herz, Alexander Franz, Salvatore M Giacomuzzi, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2009
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hoppingStefan Tasler, Oliver Müller, Tanja Wieber, et al.
Leukemia & Lymphoma|August 31, 2018
Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE studyJan Walewski, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, et al.
Antiviral Research|October 24, 2013
Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesisManfred Marschall, Ina Niemann, Karin Kosulin, et al.
Bioorganic & Medicinal Chemistry|August 21, 2009
Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimizationStefan Tasler, Oliver Müller, Tanja Wieber, et al.
Journal for Immunotherapy of Cancer|May 8, 2019
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapySonja Althammer, Tze Heng Tan, Andreas Spitzmüller, et al.
Journal of Hepatology|March 9, 2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.
Pageof 1